PMID- 34387827
OWN - NLM
STAT- MEDLINE
DCOM- 20211230
LR  - 20211230
IS  - 1993-0402 (Electronic)
IS  - 1672-0415 (Linking)
VI  - 28
IP  - 1
DP  - 2022 Jan
TI  - Qishen Taohong Granule () as Adjuvant Therapy for Improving Cardiac Function and 
      Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled 
      Trial.
PG  - 12-19
LID - 10.1007/s11655-021-2866-z [doi]
AB  - OBJECTIVE: To confirm the improvement of cardiac function and quality of life 
      (QOL) in patients with chronic heart failure (CHF) via Chinese medicine (CM) 
      Qishen Taohong Granule (, QTG). METHODS: This study was a single-center, 
      prospective, randomized, controlled clinical trial. Seventy-six patients from 27 
      to 84 years old diagnosed with CHF New York Heart Association (NYHA) class II or 
      III in stage C were enrolled and randomly assigned at a 1:1 ratio to receive QTG 
      or trimetazidine (TMZ), in addition to their standard medications for the 
      treatment of CHF. The study period was 4 weeks. The primary outcomes included 
      cardiac function evaluated by NYHA classification and left ventricular ejection 
      fraction (LVEF), as well as QOL evaluated by CHF Integrated Chinese and Western 
      Medicine Survival Scale (CHFQLS). The secondary outcomes included 6-min walking 
      test (6MWT), CM syndrome score, symptom and sign scores and N-terminal pro-B-type 
      natriuretic peptide (NT-proBNP). All indices were measured at baseline and the 
      end of the trial. RESULTS: At the 4-week follow-up period, the effective rate 
      according to NYHA classification in the QTG group was better than that in the TMZ 
      group (74.29% vs. 54.29%, P<0.05). But there was no significant difference in 
      post-treatment level of LVEF between the two groups (P>0.05). The CHFQLS scores 
      improved by 13.82+/-6.04 vs. 7.49+/-2.28 in the QTG and TMZ groups, respectively 
      (P<0.05). Subgroup analysis of the CHFQLS results showed that physiological 
      function, role limitation and vitality were significantly higher in the QTG group 
      than in the TMZ group (15.76+/-7.85 vs. 7.40+/-3.36, P<0.05; 16.00+/-8.35 vs. 
      10.53+/-4.64, P<0.05; 15.31+/-8.09 vs. 7.89+/-4.60, P<0.05). Compared with TMZ group, 
      treatment with QTG also demonstrated superior performance with respect to 6MWT, 
      CM syndrome, shortness of breath, fatigue, gasping, general edema and NT-proBNP 
      level. No significant adverse reactions or adverse cardiac events occurred during 
      treatment in either group. CONCLUSION: In addition to conventional treatments, 
      the use of QTG as an adjuvant therapy significantly improved cardiac function and 
      QOL in patients with CHF class II or III in stage C. [Registration No. 
      ChiCTR1900022036 (retrospectively registered)].
CI  - (c) 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press 
      and Springer-Verlag GmbH Germany, part of Springer Nature.
FAU - Li, Xing-Xing
AU  - Li XX
AD  - Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 
      100029, China.
FAU - Wu, Yang
AU  - Wu Y
AD  - Department of Cardiology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100078, China.
FAU - Fan, Zong-Jing
AU  - Fan ZJ
AD  - Department of Cardiology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100078, China.
FAU - Cui, Jie
AU  - Cui J
AD  - Department of Cardiology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100078, China.
FAU - Li, Dong
AU  - Li D
AD  - Department of Cardiology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100078, China.
FAU - Lin, Quan
AU  - Lin Q
AD  - Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical 
      Sciences, Beijing, 100091, China.
FAU - Zhuang, Rui
AU  - Zhuang R
AD  - Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 
      100029, China.
FAU - Yan, Rong-Kun
AU  - Yan RK
AD  - Department of Graduate School, Beijing University of Chinese Medicine, Beijing, 
      100029, China.
FAU - Lin, Qian
AU  - Lin Q
AD  - Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100700, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Cardiology, Dongfang Hospital, Beijing University of Chinese 
      Medicine, Beijing, 100078, China. 15801434320@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210813
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Peptide Fragments)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chronic Disease
MH  - Double-Blind Method
MH  - *Heart Failure/drug therapy
MH  - Humans
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain
MH  - Peptide Fragments
MH  - Prospective Studies
MH  - *Quality of Life
MH  - Stroke Volume
MH  - Ventricular Function, Left
OTO - NOTNLM
OT  - Chinese medicine
OT  - Qishen Taohong Granule
OT  - cardiac function
OT  - chronic heart failure
OT  - quality of life
EDAT- 2021/08/14 06:00
MHDA- 2021/12/31 06:00
CRDT- 2021/08/13 12:23
PHST- 2020/12/03 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2021/12/31 06:00 [medline]
PHST- 2021/08/13 12:23 [entrez]
AID - 10.1007/s11655-021-2866-z [pii]
AID - 10.1007/s11655-021-2866-z [doi]
PST - ppublish
SO  - Chin J Integr Med. 2022 Jan;28(1):12-19. doi: 10.1007/s11655-021-2866-z. Epub 
      2021 Aug 13.